NSEAnalysts/Institutional Investor Meet/Con. Call Updates5 Aug 2026 · 5 Aug 2026, 05:03 pm
Analysts/Institutional Investor Meet/Con. Call Updates
Jubilant Pharmova Limited · JUBLPHARMA
✦ AI SummaryMgmt Change
Jubilant Pharmova Limited has informed the Exchange about a scheduled meeting with institutional investors and analysts on August 13-14, 2026, to discuss Q1'FY27 earnings presentation.
Analysis Scores
Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk1/10
Liquidity Impact8/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Jubilant Pharmova Limited has informed the Exchange about Schedule of meet
Attachments (1)
📄pdf
Download →
JUBLPHARMA_05082026165919_IntimationofInvestorsAnalystsMeetin13082026signed.pdf
View document text
August 05, 2026
BSE Limited National Stock Exchange of India Limited
Phiroze Jeejeebhoy Towers, Exchange Plaza, 5th Floor,
Dalal Street, Fort, Bandra-Kurla Complex,
Mumbai - 400 001 Bandra (E), Mumbai - 400051
Scrip Code: 530019 Symbol: JUBLPHARMA
Sub.: Intimation of Investors/ Analysts Meeting
Dear Sirs,
Pursuant to the provisions of Regulation 30 of the Securities and Exchange Board of India (Listing
Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the
management of the Company shall be physically meeting the following institutional investors on August
13, 2026 to August 14, 2026, in one-on-one / group meetings in Mumbai. These meetings are organized
by Emkay Global Financial Services as a part of their Flagship Conference (Emkay Confluence). The
schedule may undergo change due to exigencies on the part of Investors / Analysts / Company.
1. HDFC AMC
2. ICICI Prudential AMC
3. Karma Capital
4. Motilal Oswal AMC
5. ICICI Prudential Life Insurance
6. ITI Mutual Fund
7. Tata Asset Management
8. MK Ventures
In the meetings, we shall discuss the Q1’FY27 Earnings presentation that shall be filed on 10th Aug, 2026
post-disclosing Q1’FY27 financial results.
This is for your information and record.
Thanking you,
Yours faithfully,
For Jubilant Pharmova Limited
Naresh Kapoor
Company Secretary